Archives: Speakers

Jackie has 20 years of experience in labelling and artwork management solutions, from solution development, to consulting, and account management. Her focus is on identifying process improvement opportunities, sharing best practices, and recommending technology-based solutions to support getting products to market faster, increasing quality and reducing risk.

Larry Zeifman has over four decades of experience auditing and advising public and private companies. After leaving a ‘Big Four’ firm in 1985 to join Zeifmans, Larry served as the firm’s Managing Partner and continues to serve on its management committee.

Specializing in auditing and consulting, Larry is responsible for servicing many of Zeifmans’ larger corporate clients, especially clients in the healthcare, cannabis and psychedelics sectors. Leader of Zeifmans’ Cannabis and Psychedelics Team, Larry advises his clients on a variety of domestic financial matters, as well as issues relating to the global corporate environment.

In 2020, Larry launched and hosted Zeifmans’ podcast series Micro-dosing with Zeifmans – demystifying the business of psychedelics, where he was joined by industry expert guests on a weekly basis to explore the latest data, trends and insights in the psychedelics industry.

Larry’s understanding of global business facilitates his chairmanship of Nexia Canada (the Canadian division of Nexia International, Zeifmans’ international network), and his membership on Nexia International’s marketing and business development committee.

With 25 years’ experience working in marketing and business development, Charlie has a comprehensive background in working closely with global brands to more effectively communicate with their key customers across a diverse range of platforms. His focus for the last 10 years has been managing and growing key client partnerships throughout EMEA and APAC. 

Morten Lind Jensen is VP of Medical Science at UNION Therapeutics A/S. Prior to working at UNION, Morten has 9 years of experience as medical specialist, project manager and line manager from Novo Nordisk, where he worked across the internal Novo Nordisk portfolio and established external collaboration projects within new ways of doing clinical trials and using digital data.

Prior to joining the pharmaceutical industry, Morten did his Ph.D. within the research space of medical education, and on how to optimize learning outcomes during the training of professionals. He has also worked clinically as a medical doctor within radiology and surgery.

Morten is an MD from University of Copenhagen, Denmark.

I am director of IND & Phase I (which includes clinical operation) in Symphogen/Servier (Symphogen was acquired by Servier in 2020)

I have worked several years in a CRO and the industry as CRA, Senior CRA and PM before joining Symphogen in 2010, where I am now heading the IND & Phase I entity which includes clinical operation but also the responsibility of facilitating new compounds (mAb) when received a go to be explored in FIH to FPFV. Symphogen develops mAb within oncology.